Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment.
Giannatempo P, Paolini B, Miceli R, Raggi D, Nicolai N, Farè E, Catanzaro M, Biasoni D, Torelli T, Stagni S, Piva L, Mariani L, Salvioni R, Colecchia M, Gianni AM, Necchi A. Giannatempo P, et al. Among authors: fare e. J Urol. 2013 Nov;190(5):1919-24. doi: 10.1016/j.juro.2013.04.057. Epub 2013 Apr 25. J Urol. 2013. PMID: 23624209
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Necchi A, Nicolai N, Mariani L, Lo Vullo S, Giannatempo P, Raggi D, Farè E, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Milani A, Gianni AM, Salvioni R. Necchi A, et al. Among authors: fare e. Clin Genitourin Cancer. 2014 Feb;12(1):63-69.e1. doi: 10.1016/j.clgc.2013.07.005. Epub 2013 Oct 23. Clin Genitourin Cancer. 2014. PMID: 24161525 Clinical Trial.
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center.
Necchi A, Giannatempo P, Lo Vullo S, Farè E, Raggi D, Marongiu M, Scanagatta P, Duranti L, Giovannetti R, Girelli L, Nicolai N, Piva L, Biasoni D, Torelli T, Catanzaro M, Stagni S, Maffezzini M, Gianni AM, Mariani L, Pastorino U, Salvioni R. Necchi A, et al. Among authors: fare e. Clin Genitourin Cancer. 2015 Feb;13(1):87-93.e1. doi: 10.1016/j.clgc.2014.06.014. Epub 2014 Jun 24. Clin Genitourin Cancer. 2015. PMID: 25044148
Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors.
Raggi D, Giannatempo P, Miceli R, Farè E, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Marongiu M, Gianni AM, Nicolai N, Salvioni R, Necchi A. Raggi D, et al. Among authors: fare e. Am J Clin Oncol. 2017 Feb;40(1):60-65. doi: 10.1097/COC.0000000000000113. Am J Clin Oncol. 2017. PMID: 25089532
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
Necchi A, Farè E, Vullo SL, Giannatempo P, Raggi D, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Verzoni E, Grassi P, Procopio G, Pizzocaro G, Mariani L, Salvioni R. Necchi A, et al. Among authors: fare e. Clin Genitourin Cancer. 2015 Aug;13(4):385-391.e1. doi: 10.1016/j.clgc.2015.02.002. Epub 2015 Feb 7. Clin Genitourin Cancer. 2015. PMID: 25726505
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis.
Necchi A, Giannatempo P, Raggi D, Mariani L, Colecchia M, Farè E, Monopoli F, Calareso G, Ali SM, Ross JS, Chung JH, Salvioni R. Necchi A, et al. Among authors: fare e. Eur Urol. 2019 Jan;75(1):201-203. doi: 10.1016/j.eururo.2018.09.010. Epub 2018 Sep 19. Eur Urol. 2019. PMID: 30243800 Clinical Trial. No abstract available.
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes.
Necchi A, Nicolai N, Mariani L, Raggi D, Farè E, Giannatempo P, Catanzaro M, Biasoni D, Torelli T, Stagni S, Milani A, Piva L, Pizzocaro G, Gianni AM, Salvioni R. Necchi A, et al. Among authors: fare e. Ann Oncol. 2013 Nov;24(11):2887-92. doi: 10.1093/annonc/mdt271. Epub 2013 Jul 16. Ann Oncol. 2013. PMID: 23860612 Free article.
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz LH, Morosi C, Crippa F, Farè E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud FG, Salvioni R, Daidone MG, Gianni AM, Mariani L. Necchi A, et al. Among authors: fare e. Br J Cancer. 2014 Jan 7;110(1):26-33. doi: 10.1038/bjc.2013.719. Epub 2013 Nov 14. Br J Cancer. 2014. PMID: 24231947 Free PMC article. Clinical Trial.
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.
Necchi A, Giannatempo P, Mariani L, Farè E, Raggi D, Pennati M, Zaffaroni N, Crippa F, Marchianò A, Nicolai N, Maffezzini M, Togliardi E, Daidone MG, Gianni AM, Salvioni R, De Braud F. Necchi A, et al. Among authors: fare e. Invest New Drugs. 2014 Jun;32(3):555-60. doi: 10.1007/s10637-014-0074-9. Epub 2014 Feb 26. Invest New Drugs. 2014. PMID: 24566706 Clinical Trial.
38 results